This study focuses on individuals living with asthma, a long-term condition that affects the airways in the lungs and can make breathing difficult. The research involves the use of lunsekimig, also known by the code SAR443765, which is administered via subcutaneous injection, meaning the medication is delivered through a needle just under the skin. The goal of this research is to evaluate the long-term safety and effectiveness of this treatment in adults with moderate-to-severe asthma.

Participants in this study are those who previously took part in earlier research trials. During this phase, the medication is given over an extended period to monitor how the body responds over time. This includes watching for any adverse events, which are unwanted or harmful medical occurrences, and observing the frequency of asthma exacerbations, which are sudden worsening of symptoms or attacks. The study also tracks changes in lung function and how the treatment affects daily life and breathing ease.